I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3898人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088775, encodeId=8af32088e7552, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=61, createdTime=2020-03-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088794, encodeId=527d2088e94a8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=191296, objectId=4009191296a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4009191296a0, replyNumber=0, likeNumber=75, createdTime=2020-08-23, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4009191296a0, moduleTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4009191296a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088801, encodeId=04dc208880198, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, objectType=article, longId=193386, objectId=63df19338615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df19338615, replyNumber=0, likeNumber=69, createdTime=2020-10-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df19338615, moduleTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df19338615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, objectType=article, longId=194057, objectId=3dae19405ec5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dae19405ec5, replyNumber=0, likeNumber=88, createdTime=2021-02-09, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dae19405ec5, moduleTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dae19405ec5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088812, encodeId=a40f20888123e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, objectType=article, longId=196814, objectId=693e19681493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e19681493, replyNumber=0, likeNumber=53, createdTime=2020-10-22, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e19681493, moduleTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693e19681493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088813, encodeId=ea962088813f3, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验, objectType=article, longId=197270, objectId=3bb219e27057, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bb219e27057, replyNumber=0, likeNumber=67, createdTime=2020-09-09, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bb219e27057, moduleTitle=ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bb219e27057)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088817, encodeId=ac87208881ef9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, objectType=article, longId=198327, objectId=861219832eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861219832eff, replyNumber=0, likeNumber=58, createdTime=2020-11-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861219832eff, moduleTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861219832eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088782, encodeId=a3652088e827a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=基因疗法URO-902治疗膀胱过度活动症：I期临床试验取得积极结果, objectType=article, longId=187516, objectId=50c918e5164f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50c918e5164f, replyNumber=0, likeNumber=67, createdTime=2020-09-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50c918e5164f, moduleTitle=基因疗法URO-902治疗膀胱过度活动症：I期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50c918e5164f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088779, encodeId=30922088e7987, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性, objectType=article, longId=186953, objectId=314a18695378, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=314a18695378, replyNumber=0, likeNumber=85, createdTime=2020-06-23, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=314a18695378, moduleTitle=急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=314a18695378)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088810, encodeId=763b208881091, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, objectType=article, longId=196105, objectId=041919610548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=041919610548, replyNumber=0, likeNumber=67, createdTime=2021-03-03, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=041919610548, moduleTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=041919610548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088790, encodeId=6d6c2088e907c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Nature：新冠mRNA疫苗I期临床试验在美国开展, objectType=article, longId=190285, objectId=6b37190285b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b37190285b3, replyNumber=0, likeNumber=93, createdTime=2020-04-19, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b37190285b3, moduleTitle=Nature：新冠mRNA疫苗I期临床试验在美国开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b37190285b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088809, encodeId=aa89208880992, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, objectType=article, longId=195935, objectId=1c30195935d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c30195935d4, replyNumber=0, likeNumber=134, createdTime=2020-10-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c30195935d4, moduleTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c30195935d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088808, encodeId=787f2088808df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=全球**新冠病毒中和抗体LY-CoV555进入I期临床试验，首批患者给药完成, objectType=article, longId=195277, objectId=a2901952e748, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2901952e748, replyNumber=0, likeNumber=63, createdTime=2021-03-31, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2901952e748, moduleTitle=全球**新冠病毒中和抗体LY-CoV555进入I期临床试验，首批患者给药完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2901952e748)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088796, encodeId=ae562088e963f, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, objectType=article, longId=192022, objectId=d2621920220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2621920220a, replyNumber=0, likeNumber=81, createdTime=2021-03-06, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2621920220a, moduleTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2621920220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088766, encodeId=139a2088e666d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=超快速作用胰岛素候选产品At247：已开始I期临床试验, objectType=article, longId=180552, objectId=5f9918055237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f9918055237, replyNumber=0, likeNumber=101, createdTime=2019-10-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f9918055237, moduleTitle=超快速作用胰岛素候选产品At247：已开始I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f9918055237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088805, encodeId=f2bd20888059f, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=张伯礼：加快新冠病毒疫苗III期临床试验, objectType=article, longId=194542, objectId=0f3a194542ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3a194542ed, replyNumber=0, likeNumber=91, createdTime=2020-12-06, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3a194542ed, moduleTitle=张伯礼：加快新冠病毒疫苗III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3a194542ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088788, encodeId=1e9a2088e88ef, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=56, createdTime=2020-08-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088798, encodeId=25b02088e989d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, objectType=article, longId=192391, objectId=50af192391d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50af192391d8, replyNumber=0, likeNumber=55, createdTime=2020-06-01, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50af192391d8, moduleTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50af192391d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088780, encodeId=20502088e8014, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, objectType=article, longId=187514, objectId=65e518e5149c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e518e5149c, replyNumber=0, likeNumber=50, createdTime=2020-12-08, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e518e5149c, moduleTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e518e5149c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, objectType=article, longId=180576, objectId=5f001805e6d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f001805e6d8, replyNumber=0, likeNumber=85, createdTime=2020-01-16, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f001805e6d8, moduleTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f001805e6d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-03-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始

2020-08-23

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验

2020-10-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动

2021-02-09

仁心济世 (审核中...)

前往app查看评论内容

#I期临床试验#

Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果

2020-10-22

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验

2020-09-09

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行

2020-11-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

基因疗法URO-902治疗膀胱过度活动症：I期临床试验取得积极结果

2020-09-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性

2020-06-23

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切

2021-03-03

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Nature：新冠mRNA疫苗I期临床试验在美国开展

2020-04-19

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验

2020-10-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

全球**新冠病毒中和抗体LY-CoV555进入I期临床试验，首批患者给药完成

2021-03-31

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果

2021-03-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

超快速作用胰岛素候选产品At247：已开始I期临床试验

2019-10-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

张伯礼：加快新冠病毒疫苗III期临床试验

2020-12-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-08-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组

2020-06-01

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验

2020-12-08

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

SCO-101治疗转移性结直肠癌患者的II期临床试验已开始

2020-01-16

科室
- - 订阅+
  - 更多科室
工具
服务